Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.36 |
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26032037 | 1.00 | GLP1R (0.52) | GLP1RLPAR3TLR2OPRK1HPGD | |
| SCHEMBL26032035 | 1.00 | GLP1R (0.52) | GLP1RLPAR3TLR2OPRK1HPGD | |
| SCHEMBL26032052 | 0.95 | GLP1R (0.48) | GLP1ROPRK1LPAR1 | |
| SCHEMBL26032060 | 0.95 | GLP1R (0.47) | GLP1RLPAR1 | |
| SCHEMBL26032096 | 0.94 | GLP1R (0.48) | GLP1RLPAR3TLR2OPRK1SIRT2 | |
| SCHEMBL26032226 | 0.91 | HPGD (0.43) | GLP1RHPGDHTTSMN1; SMN2LPAR1 | |
| SCHEMBL26032046 | 0.91 | GLP1R (0.44) | GLP1RHPGD | |
| SCHEMBL24589077 | 0.89 | GLP1R (0.55) | GLP1RTLR2OPRK1SIRT2 | |
| SCHEMBL26972994 | 0.88 | GLP1R (0.46) | GLP1RTLR2OPRK1NOD1SIRT2 | |
| SCHEMBL24589064 | 0.86 | GLP1R (0.46) | GLP1RTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | GLP1R 1683/4885LPAR3 1763/4885TLR2 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.